IP Library Granted Patent US 10,036,723
Granted Patent B2
US 10,036,723 · App. 15/185,941 · Granted Jul 31, 2018

Measurement and uses of oxidative status

Inventors: David Bar-Or (Englewood, CO); Raphael Bar-Or (Denver, CO)
Assignee: AYTU BIOSCIENCE, INC.
G01N27/4168G01N27/26G01N27/327G01N33/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,036,723
App. No.
15/185,941
Granted
Jul 31, 2018
Kind
B2
Abstract

The present invention provides a method of determining the overall oxidative status of a body fluid or a tissue of a patient by measuring the oxidation-reduction potential (ORP) of the body fluid or tissue. The method has been found to be useful in the diagnosis, evaluation and monitoring of patients who have suffered a trauma (such as a head injury), patients suspected of being critically-ill or who are critically ill, patients who have an infection, and patients suspected of having a myocardial infarction (MI) or who have had an MI. The method has also been found useful in monitoring and evaluating exercise performance in patients. In addition, the method has been found useful in monitoring and evaluating stored blood products and patients who will receive such a product.

Claims (10)

1. A method of safely transfusing an individual at risk for side effects resulting from transfusion with a blood product, comprising:

a) identifying the individual as being at risk for side effects resulting from transfusion with a blood product, using a method comprising:

i) determining the oxidation-reduction potential (ORP) value of body fluid from an individual to be transfused, and, comparing the determined ORP value with the ORP value of a corresponding body fluid from a normal subject; and,

ii) identifying the individual as being at risk for transfusion-related side effects, when the determined ORP value is significantly higher than the ORP value of the body fluid from the normal subject; and,

b) transfusing the individual with a blood product containing a level of oxidative species that is lower than the level of oxidant species in the body fluid from the individual.

2. The method of claim 1 , wherein the body fluid is whole blood.

3. The method of claim 1 , wherein the body fluid is packed red blood cells.

4. The method of claim 1 , wherein the ORP value is measured by contacting the body fluid with an electrode connected to a machine that provides a readout of the ORP.

5. The method of claim 1 , wherein the body fluid is selected from the group consisting of blood, urine, saliva, cerebrospinal fluid, tears, semen, vaginal secretions, amniotic fluid, and cord blood.

6. The method of claim 1 , wherein the body fluid is serum.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2021
From: AYTU BIOSCIENCE, INC.
To: CAERUS BIOTECHNOLOGIES
Reel/Frame 057716/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2016
From: BAR-OR, DAVID; BAR-OR, RAPHAEL
To: AYTU BIOSCIENCE, INC.
Reel/Frame 039214/0906 →
Continuity (5)
Division 14222075 · Mar 21, 2014
Division 12625072 · Nov 24, 2009
Continuation In Part 12121945 · May 16, 2008
Provisional Application 60938925 · May 18, 2007
Related Publication 20160290960A1 · Oct 6, 2016